Although we’ve accomplished a great deal over the years, the fact remains that while colorectal cancer (CRC) is preventable, it continues to be a leading cause of cancer death in Canada. Moreover, we are faced with new challenges, such as rising rates of CRC in young adults and keeping up to date on advancements in research and development.
Our various initiatives allow CCC to continue to advocate for the well-being of CRC patients and those at risk.
The Foods That Fight Cancer (FTFC) program educates Canadians about incorporating healthy, nutritional and fun choices into their daily diets, providing them with recipes that will assist them in making the right food choices in helping them to prevent colorectal cancer and other cancers as well. The anti-cancer properties contained in the recipes have the additional benefit of increasing the chances of surviving cancer in the long run.
The Patient Values Project (PVP) will allow Colorectal Cancer Canada and other cancer patient groups in Canada and abroad to better capture the patient perspective when a cancer drug comes under review by a health technology assessment (HTA) authority. The Project aims to define, measure and weigh patient values and preferences before incorporating them into the HTA patient group submission.
The Patient Group Pathway Model to Accessing Cancer Clinical Trials is a Colorectal Cancer Canada (CCC) initiative which aims to increase recruitment, participation and retention rates of cancer clinical trials within Canada. A consensus meeting and a working group meeting were hosted by CCC in 2017 and recommendations on increasing uptake were published in Current Oncology in 2018. In 2018, a conference regarding The Patient Group Pathway Model and Real World Evidence Conference was hosted to draft a Patient Charter for clinical trial stakeholders. In 2019, a two-day conference was organized to foster patient group partnerships among stakeholders who advocate for cancer clinical trials in Canada and the development of Real World Evidence to help reduce uncertainty in clinical trial results.READ OUR PUBLICATION
Real World Evidence (RWE) is the third component to our patient-centric national “Trilogy” initiative. It focuses on the ability to collect data from clinical trials so that the best treatment paths can be uncovered for patients in clinical practice. CCC will be working to continue to capture the patient perspective across the continuum of colorectal cancer care.
The Get Personal Campaign promotes awareness and education for the need to get genetically tested as soon as a stage IV colorectal cancer patient is diagnosed with the disease. Identification of biomarker status is important in properly managing advanced disease. More importantly, identifying a patient’s genetic status will ensure a personalized approach to their care and treatment of their disease.
The Never Too Young (N2Y) Program brings much-needed awareness and education to the forefront when it comes to early age onset colorectal cancer. Colorectal cancer is on the rise in young people and we are committed to learning more and providing support for those currently in their fight.